CEACAM5 and non-small cell lung carcinoma: In conclusion, CEA and CYFRA21-1 may serve as realible markers of efficacy in NSCLC patients treated with nivolumab, either when considering the determination of the markers at baseline, or a markers reduction ≥ 20% after 4 cycles of nivolumab.